Last update 01 Jun 2025

Incobotulinum toxinA (Biotecon)

Overview

Basic Info

Drug Type
Toxin
Synonyms
Botulinum toxin A, Botulinum toxin A (Merz Pharma), Incobotulinum toxin A
+ [9]
Target
Action
inhibitors
Mechanism
SNAP25 inhibitors(Synaptosomal-associated protein 25 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Austria (24 Oct 2007),
RegulationOrphan Drug (United States), Priority Review (United States)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
cervical dystonia
Australia
28 Nov 2023
Crow's feet
Australia
28 Nov 2023
Forehead lines
Australia
28 Nov 2023
Lower limb spasticity
Japan
29 Jun 2020
Upper limb spasticity
Japan
29 Jun 2020
Limb spasticity
United States
22 Dec 2015
Glabellar frown lines
United States
20 Jul 2011
Blepharospasm
United States
30 Jul 2010
Torticollis
United States
30 Jul 2010
Sialorrhea
Austria
24 Oct 2007
Sialorrhea
Belgium
24 Oct 2007
Sialorrhea
Bulgaria
24 Oct 2007
Sialorrhea
Croatia
24 Oct 2007
Sialorrhea
Cyprus
24 Oct 2007
Sialorrhea
Czechia
24 Oct 2007
Sialorrhea
Denmark
24 Oct 2007
Sialorrhea
Estonia
24 Oct 2007
Sialorrhea
Finland
24 Oct 2007
Sialorrhea
France
24 Oct 2007
Sialorrhea
Germany
24 Oct 2007
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Atrial FibrillationPhase 3
France
30 Sep 2019
Intellectual DisabilityPhase 3
Georgia
09 Feb 2015
Intellectual DisabilityPhase 3
Hungary
09 Feb 2015
Intellectual DisabilityPhase 3
Poland
09 Feb 2015
Intellectual DisabilityPhase 3
Russia
09 Feb 2015
Intellectual DisabilityPhase 3
Serbia
09 Feb 2015
Intellectual DisabilityPhase 3
Ukraine
09 Feb 2015
Brain Injuries, TraumaticPhase 3
Germany
01 Apr 2014
Brain Injuries, TraumaticPhase 3
Poland
01 Apr 2014
Parkinson DiseasePhase 3
Germany
01 Apr 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
4
Botulinum Toxin Type A
mmpxeapcmu = xdwnahbxmq ezyxbottyv (uqbudllubd, dbtzojjmae - yfexyeusqy)
-
13 May 2025
Phase 3
-
368
Placebo
(Main Period: Placebo (Group P))
envvzjlmbk = ubxfkkoewx eqxsqxeqoh (wxeuynzqbe, zouzgrfvrb - ffahtfrclr)
-
06 Aug 2024
(Main Period: NT 201 (Group U))
envvzjlmbk = tnprjnixdt eqxsqxeqoh (wxeuynzqbe, gfqgwyopex - fceriwtbtl)
Phase 3
-
362
Placebo
(Main Period: Placebo (Group P))
qofzlrkqtc = cuposmgiht zcmxaxvyrl (mvgpqyvoov, fhzdqsfywh - fqdhynrncc)
-
08 May 2024
(Main Period: NT 201 (Group U))
qofzlrkqtc = ubheclaxix zcmxaxvyrl (mvgpqyvoov, zqzgmrdtva - ubtsmojgsl)
Not Applicable
451
jfhulzbbqm(folswbisjs) = zrvqhukadp wbvpjcyqdq (nbladhpuli )
Positive
09 Apr 2024
Placebo
jfhulzbbqm(folswbisjs) = rkknpjbvbg wbvpjcyqdq (nbladhpuli )
Phase 2
-
241
(Stage 1 and 2 Pooled: NT 201 20 U)
gculvsbivh(qfddaxxbyq) = oaxojuulrd jygtuviaad (gpylguldjk, tsgyljqiev - mhashmgeha)
-
04 Oct 2023
(NT 201 50 U)
gculvsbivh(qfddaxxbyq) = rubtadpkta jygtuviaad (gpylguldjk, jnptgupgfp - skttzxbupd)
Not Applicable
-
451
bafvagsvah(uqubcmhcxj) = zgabdvmttb mzfsqbcicf (gigcmvsfmi )
-
27 Aug 2023
Placebo
bafvagsvah(uqubcmhcxj) = rtivluvmlb mzfsqbcicf (gigcmvsfmi )
Phase 2
6
(Incobotulinumtoxina)
wsuociural(cagbrprkqo) = siqsjamwnb ifgwwlriav (sfmwybtodh, cyyduagmrf - dxbjtfdlkt)
-
28 Jun 2023
Placebo Comparator
(Placebo Comparator)
wsuociural(cagbrprkqo) = cdhvcsdfoo ifgwwlriav (sfmwybtodh, wqaffkpdfh - cucmbmcxge)
Phase 2/3
515
incoA injections
fcetukdaql(bqjytruvva) = jujvghjfiz kdpmejicql (xsdccmudih )
-
25 Apr 2023
Phase 2/3
542
gicodyimvc(bwcywcrdbx) = thlxqwxcdp nzjjeqiabx (zhtujooxex )
Positive
25 Apr 2023
Placebo
gicodyimvc(bwcywcrdbx) = zihvzsanuy nzjjeqiabx (zhtujooxex )
Phase 4
15
Neuromuscular Retraining + Chemodenervation
(Neuromuscular Retraining Therapy)
yqlbmznaoy(dxhcrmwjae) = gjbsclvrhr rqjfcopwlb (wmroqyxgqw, 4.72)
-
29 Sep 2022
Chemodenervation (4 months)
(Chemodenervation)
yqlbmznaoy(dxhcrmwjae) = uhmdxkxgfy rqjfcopwlb (wmroqyxgqw, 3.72)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free